ImmunityBio (IBRX) news

ImmunityBio appoints Dr. Jim Yong Kim, former World Bank president and global health leader, as vice chairman

ImmunityBio, a biotechnology company focused on developing innovative immunotherapies, has appointed Dr. Jim Yong Kim as vice chairman. Dr. Kim, a former president of the World Bank and a globally recognized leader in public health, brings extensive experience in global development and…

Shares of ImmunityBio down 2% after posting Q2 loss

ImmunityBio Q2 revenue USD 51.24 million vs. IBES estimate USD 49.7 million

ImmunityBio, Inc. (NASDAQ: IBRX) reported second-quarter 2026 total revenue of $51.24 million, exceeding the IBES estimate of $49.7 million. This represents a 92% year-over-year increase and a 15% sequential growth from the first quarter of 2026. The company’s net product revenue for the quarter…

ImmunityBio gets United Arab Emirates marketing ok for Anktiva

ImmunityBio has received regulatory approval in the United Arab Emirates for its immunotherapy treatment, ANKTIVA®. This development follows recent approvals in Saudi Arabia, where the drug was granted accelerated approval by the Saudi FDA in combination with checkpoint inhibitors for the treatment…

BiosySyn - proposes rights issue of 1 for 2 at HK$0.068 per share

Gujarat Themis Biosyn Ltd (GTBL) has recently announced a series of corporate actions, including shareholder meetings, compliance certifications, and financial disclosures, reflecting ongoing governance and operational developments. The company reported a 3.93% decline in net profit for Q3 2025,…